Document is current
Any future updates will be listed below
-
Authors
Hinz, Felix
Friedel, Dennis
Korshunov, Andrey
Ippen, Franziska M.
Bogumil, Henri
Banan, Rouzbeh
Brandner, Sebastian
Hasselblatt, Martin
Boldt, Henning B.
Dirse, Vaidas
Dohmen, Hildegard
Aronica, Eleonora
Brodhun, Michael
Broekman, Marike L. D.
Capper, David
Cherkezov, Asan
Deng, Maximilian Y.
van Dis, Vera
Felsberg, Jörg
Frank, Stephan
French, Pim J.
Gerlach, Rüdiger
Göbel, Kirsten
Goold, Eric
Hench, Jürgen
Kantelhardt, Sven
Kohlhof-Meinecke, Patricia
Krieg, Sandro
Mawrin, Christian
Morrison, Gillian
Mühlebner, Angelika
Ozduman, Koray
Pfister, Stefan M.
Poliani, Pietro Luigi
Prinz, Marco
Reifenberger, Guido
Riemenschneider, Markus J.
Sankowski, Roman
Schrimpf, Daniel
Sill, Martin
Snuderl, Matija
Verdijk, Robert M.
Voisin, Mathew R.
Wesseling, Pieter
Wick, Wolfgang
Reuss, David E.
von Deimling, Andreas
Sahm, Felix
Maas, Sybren L. N.
Suwala, Abigail K.
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (259373024, 532594103)
Bundesministerium für Bildung und Forschung (01EO2103)
Universitätsklinikum Heidelberg
- License Information
-
More Information
Article History
Received: 22 October 2024
Revised: 13 January 2025
Accepted: 14 January 2025
First Online: 3 February 2025
Declarations
:
: MS is scientific advisor and shareholder of Heidelberg Epignostix and Halo Dx, and a scientific advisor of Arima Genomics, and InnoSIGN, and received research funding from Lilly USA, and Illumina USA. DC, SMP, DS, AvD and FS are shareholders of Heidelberg Epignostix.
: Collection and analysis of corresponding tissue samples and clinical data was performed in accordance with local ethics regulations (local ethics vote S-318/2022) and in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.
